Accelerate Diagnostics, Inc.

Hello and welcome to the Accelerate Diagnostics fourth quarter and full year 2023 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Today's presentation will be followed by a question and answer session with covering analysts. As a reminder, this conference is being recorded. I would now like to hand the call to Laura Pearson with Accelerate Diagnostics. Laura, please go ahead.

Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future, and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risk, uncertainties, and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year into December 31, 2023, and other reports we follow with the SEC. It is my pleasure to now introduce the company's President and CEO, Jack Phillips.

Thank you, Laura. Good afternoon, everyone. Today, I would like to discuss the exciting innovation with WAVE. I will cover both near-term program milestones and how WAVE will revolutionize automated susceptibility testing. Additionally, I will provide updates on our strategic partnership process and our AHRQ FDA submission. First, I will pass it over to David Patience, our CFO, to summarize our financial results.